Zobrazit v EDS

Higher cholesterol levels, not statin use, are associated with a lower risk of hepatocellular carcinoma

Uloženo v:
Podrobná bibliografie
Název: Higher cholesterol levels, not statin use, are associated with a lower risk of hepatocellular carcinoma
Autoři: Sang-Wook Yi, Kijun Han, Jee-Jeon Yi, Se Hwa Kim, Heechoul Ohrr
Přispěvatelé: Sang-Wook Yi, Se Hwa Kim, Ki Jun Han, Jee-Jeon Yi, Heechoul Ohrr, Ohrr, Hee Choul
Zdroj: Br J Cancer
Informace o vydavateli: Springer Science and Business Media LLC, 2019.
Rok vydání: 2019
Témata: Male, 0301 basic medicine, Liver Neoplasms / epidemiology, Carcinoma, Hepatocellular, Liver Neoplasms / blood, Cholesterol / blood, Brief Communication, Hepatocellular / blood, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Republic of Korea, Humans, 10. No inequality, Hepatocellular / epidemiology, Republic of Korea / epidemiology, Proportional Hazards Models, Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage, Incidence, Carcinoma, Liver Neoplasms, 3. Good health, Cholesterol, Female, Hydroxymethylglutaryl-CoA Reductase Inhibitors
Popis: We aimed to examine whether statin users have a lower risk of hepatocellular carcinoma (HCC) after careful consideration of prevalent statin use and cholesterol levels. During a mean prospective follow-up of 8.4 years in 400,318 Koreans, 1686 individuals were diagnosed with HCC. When prevalent users were included, HCC risk was reduced by >50% in statin users, regardless of adjustment for total cholesterol (TC). When prevalent users were excluded, new users who initiated statins within 6 months after baseline had a 40% lower risk of HCC (hazard ratio [HR] = 0.59) in a TC-unadjusted analysis. However, this relationship disappeared (HR = 1.16, 95% CI = 0.80–1.69) after adjusting for TC levels measured within 6 months before statin initiation. TC levels had strong inverse associations with HCC in each model. High cholesterol levels at statin initiation, not statin use, were associated with reduced risk of HCC. Our study suggests no protective effect of statins against HCC.
Druh dokumentu: Article
Other literature type
Jazyk: English
ISSN: 1532-1827
0007-0920
DOI: 10.1038/s41416-019-0691-3
Přístupová URL adresa: https://www.nature.com/articles/s41416-019-0691-3.pdf
https://pubmed.ncbi.nlm.nih.gov/31857717
https://www.nature.com/articles/s41416-019-0691-3
https://www.nature.com/articles/s41416-019-0691-3.pdf
https://pubmed.ncbi.nlm.nih.gov/31857717/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054540
https://europepmc.org/article/MED/31857717
https://www.ncbi.nlm.nih.gov/pubmed/31857717
Rights: CC BY
CC BY NC ND
URL: http://creativecommons.org/licenses/by/4.0/Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
Přístupové číslo: edsair.doi.dedup.....7e5027640041e0b97c736e6a20de2c49
Databáze: OpenAIRE
Popis
Abstrakt:We aimed to examine whether statin users have a lower risk of hepatocellular carcinoma (HCC) after careful consideration of prevalent statin use and cholesterol levels. During a mean prospective follow-up of 8.4 years in 400,318 Koreans, 1686 individuals were diagnosed with HCC. When prevalent users were included, HCC risk was reduced by >50% in statin users, regardless of adjustment for total cholesterol (TC). When prevalent users were excluded, new users who initiated statins within 6 months after baseline had a 40% lower risk of HCC (hazard ratio [HR] = 0.59) in a TC-unadjusted analysis. However, this relationship disappeared (HR = 1.16, 95% CI = 0.80–1.69) after adjusting for TC levels measured within 6 months before statin initiation. TC levels had strong inverse associations with HCC in each model. High cholesterol levels at statin initiation, not statin use, were associated with reduced risk of HCC. Our study suggests no protective effect of statins against HCC.
ISSN:15321827
00070920
DOI:10.1038/s41416-019-0691-3